

09.08.2021

AN ACCREDITED CONTINUING EDUCATION SERIES WITH THE EXPERTS

Addressing Disparities in Cancer Care and Incorporating Precision Medicine for Minority Populations











Disparities in Cancer Care: Lung Cancer



Moderator & Course Director

Edith Mitchell, MD, MACP, FCPP, FRCP Clinical Professor of Medicine and Medical Oncology Department of Medical Oncology Director, Center to Eliminate Cancer Disparities Associate Director, Diversity Affairs Sidney Kimmel Cancer Center at Jefferson 116th President National Medical Association



Presenters

Narjust Duma, MD

Associate Director of the Cancer Equity Program Assistant Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts



Nathaniel Evans III, MD

Professor Director, Division of Thoracic Surgery Jefferson University Hospitals Philadelphia, Pennsylvania









Disclosure

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC or Bio Ascend.







Faculty Disclosures

Edith Mitchell, MD, MACP, FCPP, FRCP

Consultant: AstraZeneca, Bristol Myers Squibb, Genentech, Merck & Co., Inc., Pfizer Inc., Taiho Oncology, Inc.

Clinical Research: Amgen, Genentech

Planning Committee

The following planning committee members have nothing to disclose: **UNMC:** Brenda Ram, CMP, CHCP Bio Ascend: Chloe Dunnam; Lucja Grajkowska, PhD; Kraig Steubing

Narjust Duma, MD Advisory Board: AstraZeneca, Janssen, Pfizer Inc

Nathaniel Evans III, MD

Consultant: Intuitive Surgical (Proctor)











Learning Objectives

- Review racial difference in the outcomes in patients with cancer, including patients with both hematologic and solid tumors
- Evaluate sociodemographic, physician, and hospital factors that can help identify potentially modifiable patient and health care system factors that may underlie persistent racial disparities in receipt and quality of therapy
- Develop efforts to improve access to care, enhance diversity in the healthcare workforce, • navigate minority cancer patients through the healthcare system, and enhance adherence to cancer-specific best practice










Disparities in Lung Cancer

Narjust Duma, MD Associate Director of Cancer Care Equity Thoracic Oncologist Lowe Center For Thoracic Oncology Dana-Farber Cancer Institute September 2021





Cancer Disparities



SEER Cancer Incidence and US Death Rates, 2013-2017 By Cancer Site and Race/Ethnicity

SEER 21 2013–2017, Age-Adjusted Rate per 100,000.

Lung Cancer Health Disparities

- Adverse differences between certain population groups in cancer measures:
 - Incidence (LGTBQ, others)
 - Stage at diagnosis
 - Mortality
 - Survivorship
 - Screening rates
 - Access to clinical trials
 - End of life



And many more...




Lowe Center for Thoracic Oncology


O'Keefe, et al. "Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000–2010." Frontiers in public health (2015) Green, et al. "Cancer health disparities." Fundamentals of Cancer Prevention. Springer Berlin Heidelberg (2014)

Which U.S. Population Groups Experience Cancer Health Disparities?

According to the National Cancer Institute cancer health disparities in the United States are adverse differences in cancer measures such as number of new cases, number of deaths, cancer-related health complications, survivorship and quality of life after cancer treatment, screening rates, and stage at diagnosis that exist among certain population groups including:



Imerican Association for Cancer Research (AACR) Cancer Disparities Progress Report 2020



80% of a Healthy Outcome is NOT determined by Clinical Care – when someone is Sick





Practical Barriers to Healthcare

- Lack finances to purchase needed health services and treatments (e.g., medications, diagnostic tests, health provider fees)
- Transportation difficulties (e.g., no car)
- Difficulties taking leave from work to seek care (e.g., no paid leave available, employer will not allow time off)
- Difficulties arranging childcare





NSCLC and Race

The incidence rates and mortality rates of lung cancer are highest in Black men

Over the past 40 years there has been a decrease in lung cancer incidence and mortality in all races

Black men are still more likely to have lung cancer when smoking habits are adjusted for



Lung Cancer and Income

 Low income takes on special importance in lung cancer: Double jeopardy phenomenon

Low income increased risk due to tobacco Low income increases risk of dying

- Income is directly related to stage of disease at presentation
- Stage at presentation drives mortality



Lowe Center for Thoracic Oncology Albano, Jessica D., et al. "Cancer mortality in the United States by education level and race." Journal of the National Cancer Institute 99.18 (2007): 1384-1394.





ORIGINAL STUDY | VOLUME 21, ISSUE 3, E115-E129, MAY 01, 2020

Influence of Sociodemographic Factors on Treatment Decisions in Non–Small-Cell Lung Cancer

Narjust Duma 🙁 🖂 • Dame W. Idossa • Urshila Durani • ... Alex A. Adjei • Ronald S. Go •

Sikander Ailawadhi • Show all authors

Published: August 30, 2019 • DOI: https://doi.org/10.1016/j.cllc.2019.08.005 •

Check for updates





Lung-Cancer Screening

• The most effective way to dramatically improve outcomes in NSCLC is early detection

• Multiple trials have shown a significant improvement in lung- cancer survival with lung screening, despite screening at limited time points throughout the trials





Gender/Racial Differences in NLST Outcomes

- LDCT screening in NLST decreased mortality for all groups but even more so in African Americans
- Black patients were younger, with more co morbidities and less educated, but had a greater benefit
- Looking at screening rates in other diseases, raised the question of utilization of screening in vulnerable populations



Wiener, Renda Soylemez, et al. "An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice." American journal of respiratory and critical care medicine 192.7 (2015): 881-891.



More benefit from lung cancer screening?

Female v Male		Percent LC Mortality Decrease					
Ratio	(%)	Trial	Men	Women	50:50 M/F		
NLST	41/59	NLST	8%	27%	18%		
NELSON	16/84	NELSON	26%	39-61%	33 – 44%		

But less likely to be screened oxtimes





Lung Cancer Screening Discussions


	Ν	Events	Age-Adj	usted		Multiva	riable-Adju	ste l ¹
Sex ²			OR	Upper CI	Lower CI	OR	Upper C	ower CI
Female	2356	176	0.72	0.53	0.99	0.64	0.45	0.92
Male	1851	199	1.00	reference		1.00	reference	
Race ³								
Hispanic	467	53	1.32	0.88	1.98	1.81	1.09	3.01
Non-Hispanic White	2887	238	1.00	reference		1.00	reference	
Non-Hispanic Black	600	59	1.48	0.99	2.22	1.53	0.98	2.37
Non-Hispanic Asian or Other Race	253	25	1.37	0.78	2.41	2.16	1.12	4.17
Race/Sex ⁴								
Hispanic male	204	31	1.34	0.77	2.35	1.61	0.83	3.10
Hispanic female	263	22	0.85	0.45	1.63	1.13	0.55	2.34
NH-White male	1328	132	1.00	reference		1.00	reference	
NH-White female	1559	106	0.66	0.46	0.94	0.55	0.37	0.82
NH-Black male	209	27	1.34	0.65	2.76	1.18	0.52	2.65
NH-Black female	391	32	1.14	0.71	1.84	1.07	0.63	1.83
NH-Asian/other male	110	9	0.82	0.36	1.86	1.12	0.42	2.95
NH-Asian/other female	143	16	1.44	0.59	3.51	2.26	0.82	6.24
Survey Cycle ⁵								
4.2 (2013)	1272	153	1.00			1.00		
4.4 (2015)	1486	107	0.43	0.31	0.61	0.41	0.27	0.61
5.1 (2017)	1449	115	0.64	0.45	0.89	0.64	0.44	0.93

Inclusion in Lung Cancer Clinical Trials

Representation in Clinical Trials - Challenge

• Decline in the recruitment of minorities, women and the elderly in the past 14 years

	No. of Trial Enrollees		2013 Cancer Prevalence	EF	
Racial/Ethnic Group	No.	%	%	%	
All cancers					
Non-Hispanic white	46,431	83.4	79.0	1.2	
African American	3,270	6.0	10.0	0.7	
Hispanic	1,484	2.6	7.0	0.4	
Asian/Pacific Islander	2,982	5.3	3.3	1.9	
American Indian/Alaskan	190	0.3	0.3	1.3	
Native					
Other	1,332	2.4			



Duma, Narjust, et al. "Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years." Journal of oncology practice 14.1 (2017)



Limited to Subgroups – Challenge

Most studies focused on a population subgroup, in a specific geographic location, limiting the <u>generalizability</u> of the findings








Lung Cancer Biomarker Testing





Institutions Adopting EGFR assay

- Medicare claims data from 2010-2013
- Geographic area was most powerful predictor
- Medicaid status
- Race (Black patients less likely Asian patients more likely)
- Distance from NCI cancer center







Lynch, Julie A., et al. "Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research." Genetics in Medicine 15.8 (2013): 630-638.

Molecular Testing Update

• Kehl et. al. JNCI 2019

SEER-Medicare 2008-2013 molecular testing adenocarcinoma over 5000 pts.


- AA 14% White 26% Asian 33%
- 20% poorest census tract vs 30 % top income tract
- Testing rates for all improved over time
- Dual eligible Medicaid, race, poverty were significant
- Being seen at an NCI center powerful positive effect





Multilevel Approach - Challenge


- It is not all about stage at diagnosis!
- Biobanks Majority samples are from non-Hispanic White patients
- Palliative care Hospice





Polite, Blase N., et al. "Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute." CA: a cancer journal for clinicians (2017)





Intersectionality Racism Different races are People of different disproportionately genders experience affected by classism racism differently **Sexism** Classism People of different genders are affected by classism in unique ways

The COVID-19 pandemic has disrupted the spectrum of cancer care, including delaying diagnoses and treatment and halting clinical trials






Widened Disparities Gap

- Loss of Job/Economic Insecurity
- Population Density
- Public Transport Dependency
- High Contact Risk Jobs
- Comorbidities
- Digital Divide
- Fear
- Loss of Insurance






Farley JH, et al. Gynecol Oncol. 2020 l;158(1):25-31.

COVID-19: Delays in Lung Cancer Screening Associated with Rise in Malignancy Rates at a Single Institution

During COVID-19 restrictions, patient visits decreased for low-dose computed tomography (LDCT) lung cancer screening **2020 Timeline** / March 13 > **LDCT suspended** / May 5 > **phased reopening** / June 1 > **full opening**



journalacs.org

Van Haren RM, et al. J Am Coll Surg 2020. doi.org/10.1016/j.jamcollsurg.2020.12.002 Study conducted at University of Cincinnati College of Medicine

Steps taken to increase patient visits


- More patient education—why screening is safe
- Move screening from hospital to outpatient center
- Social distancing in waiting rooms, screening areas
- Space appointments further apart



Journal of the American College of Surgeons **Physician bias:**

"Poor compliance"

"Lack of understanding" – Language Barrier?







How to measure systemic racism and discrimination during crisis?





Use YOUR privilege to create EQUITY

Sidney Kimmel Cancer Center Jefferson Health_® | NCI – designated

Until every cancer is cured

Disparities in Lung Cancer

Screening, Diagnosis, Treatment and Outcomes

Nathaniel R. Evans III, MD, FACS, FCCP Professor of Surgery Director, Division of Thoracic and Esophageal Surgery @NateEvansMD

Sept 8, 2021

Disclosures

None

(well... I am a Thoracic Surgeon and Surgery is the most effective treatment for lung cancer)



Until every cancer is cured

Lung Cancer

			Males	Females			
Prostate	191,930	21%			Breast	276,480	30%
Lung & bronchus	116,300	13%			Lung & bronchus	112,520	129
Colon & rectum	78,300	9%		T	Colon & rectum	69,650	89
Urinary bladder	62,100	7%			Uterine corpus	65,620	79
Melanoma of the skin	60,190	7%			Thyroid	40,170	49
Kidney & renal pelvis	45,520	5%			Melanoma of the skin	40,160	49
Non-Hodgkin lymphoma	42,380	5%			Non-Hodgkin lymphoma	34,860	49
Oral cavity & pharynx	38,380	4%			Kidney & renal pelvis	28,230	39
Leukemia	35,470	4%			Pancreas	27,200	35
Pancreas	30,400	3%			Leukemia	25,060	35
All Sites				_			
nated Deaths	893,660	100%			All Sites	912,930	1005
	893,660	100%	Males	Females		912,930	1005
	893,660 	23%	Majes	Females		912,930 63,220	
nated Deaths			Majes	Females			225
nated Deaths Lung & bronchus	72,500	23%	Majes	Females	Lung & bronchus	63,220	225
nated Deaths Lung & bronchus Prostate	72,500 33,330	23% 10%	Majes	Females	Lung & bronchus Breast	63,220 42,170	224 155 94
nated Deaths Lung & bronchus Prostate Colon & rectum	72,500 33,330 28,630	23% 10% 9%	Males	Females	Lung & bronchus Breast Colon & rectum	63,220 42,170 24,570	225 155 95 85
Lung & bronchus Prostate Colon & rectum Pancreas	72,500 33,330 28,630 24,640	23% 10% 9% 8%	Majes	Females	Lung & bronchus Breast Colon & rectum Pancreas	63,220 42,170 24,570 22,410	229 159 99 89
Lung & bronchus Prostate Colon & rectum Pancreas Liver & Intrahepatic bile duct Leukemia	72,500 33,330 28,630 24,640 20,020	23% 10% 9% 8% 6%	Majes	5	Lung & bronchus Breast Colon & rectum Pancreas Ovary	63,220 42,170 24,570 22,410 13,940	229 159 99 89 59
nated Deaths Lung & bronchus Prostate Colon & rectum Pancreas Liver & intrahepatic bile duct Leukemia Esophagus	72,500 33,330 28,630 24,640 20,020 13,420	23% 10% 9% 8% 6% 4%	Majes	5	Lung & bronchus Breast Colon & rectum Pancreas Ovary Uterine corpus	63,220 42,170 24,570 22,410 13,940 12,590	1009 229 159 99 89 59 49 49 39
Lung & bronchus Prostate Colon & rectum Pancreas Liver & Intrahepatic bile duct Leukemia Esophagus Urinary biadder	72,500 33,330 28,630 24,640 20,020 13,420 13,100	23% 10% 9% 8% 6% 4%	Majes	5	Lung & bronchus Breast Colon & rectum Pancreas Ovary Uterine corpus Liver & intrahepatic bile duct	63,220 42,170 24,570 22,410 13,940 12,590 10,140	229 159 99 89 59 49

All Sites

285,360

100%

All Sites


321,160

100%

Sidney Kimmel Cancer Center Jefferson Health. NCI - designated

Until every cancer is cured

Checkpoint inhibitors/Immunotherapy are great!





PATIENTS WITH ADVANCED LUNG CANCER THAN ANY OTHER IMMUNOTHERAPY


IT'S TRU. KEYTRUDA.

J Clin Oncol 37:537-546.




Until every cancer is cured

Checkpoint inhibitors/Immunotherapy are great! But...




J Clin Oncol 37:537-546.





Disparities in Immunotherapy Use

- NCBD Study
- ~500,000 patients
- 2004-2015



Sidney Kimmel Cancer Center Jefferson Health J Immunother 2019;42:55-64

Surgery is a big part of the problem (and the solution)






Figure 2. Survival of Medicare Beneficiaries 65 Years of Age or Older Who Were Given a Diagnosis of Stage I or II Non-Small-Cell Lung Cancer between 1985 and 1993, According to Race.



Sidney Kimmel Cancer Center Jefferson Health

RACIAL DIFFERENCES IN THE TREATMENT OF EARLY-STAGE LUNG CANCER



NO. OF PATIENTS AT R	ISK					
White, surgery	7763	4495	2255	1069	407	12
Black, surgery	550	301	145	69	30	0
White, no surgery	2361	458	110	30	6	0
Black, no surgery	310	60	14	2	1	0

Figure 1. Survival of Medicare Beneficiaries 65 Years of Age or Older Who Were Given a Diagnosis of Stage I or II Non-Small-Cell Lung Cancer between 1985 and 1993, According to Treatment and Race.

N Engl J Med 1999;341:1198-205

Guideline concordant care

Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States

Erik F. Blom^{1,2*}, Kevin ten Haaf¹, Douglas A. Arenberg², and Harry J. de Koning¹

¹Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; and ²Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan

ORCID ID: 0000-0002-2016-5668 (E.F.B.).


"Many patients with lung cancer in the United States received no treatment or less intensive treatment than recommended. Particularly, elderly patients with lung cancer and non-Hispanic black patients are less likely to receive guideline-concordant treatment."

Ann Am Thorac Soc Vol 17, No 2, pp 186–194, Feb 2020

Sidney Kimmel Cancer Center Jefferson Health。 | NCI – designated



Racial disparities in local therapy for early stage non-small-cell lung cancer



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

AUGUST 4, 2011

VOL. 365 NO. 5

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

The National Lung Screening Trial Research Team*



N Engl J Med 2011;365:395-409

Sidney Kimmel Cancer Center Jefferson Health

Table 1. Selected Baseline Characteristics of the Study Participants.* Low-Dose CT Group Radiography Group Characteristic (N = 26,722)(N = 26,732)number (percent) Age at randomization <55 yr† 2 (<0.1) 4 (<0.1) 55-59 yr 11,440 (42.8) 11,420 (42.7) 60-64 yr 8,170 (30.6) 8,198 (30.7) 4,756 (17.8) 4,762 (17.8) 65-69 yr 70-74 yr 2,353 (8.8) 2,345 (8.8) ≥75 yr† 1 (<0.1) 3 (<0.1) Sex Male 15,762 (59.0) 15,770 (59.0) Female 10,952 (41.0) 10,970 (41.0) Race or ethnic group White 24,260 (90.8) 24,289 (90.9) ,195 (1.5 Васк 1,181 (4.4) Asian 559 (2.1) 536 (2.0) American Indian or Alaska 92 (0.3) 98 (0.4) Native Native Hawaiian or other 91 (0.3) 102 (0.4) Pacific Islander More than one race or ethnic 333 (1.2) 346 (1.3) group Data missing 163 (0.6) 209 (0.8) Hispanic ethnic group: Hispanic or Latino 479 (1.8) 456 (1.7) Neither Hispanic nor Latino 26,079 (97.6) 26,039 (97.4) Data missing 164 (0.6) 237 (0.9) Smoking status 12,900 (48.3) Current 12,862 (48.1) 13,860 (51.9) 13,832 (51.7) Former

Inadequate risk assessment tools

Research Letter | Oncology Association of Race With Lung Cancer Risk Among Adults Undergoing Lung Cancer Screening

Christine S. Shusted, MPH; Nathaniel R. Evans, MD; Hee-Soon Juon, MSN, PhD; Gregory C. Kane, MD; Julie A. Barta, MD

Studied the validity of well-established cancer risk calculators

<u>Common risk calculators failed to predict lung cancer in African</u> <u>American patients</u>

JAMA Network Open, *4*(4), e214509

Sidney Kimmel Cancer Center Jefferson Health。 | NCI – designated

Disparities in Lung Cancer Screening

- Black patients have higher risk of cancer per pack year smoked
- Black patients are less likely to be "eligible" for lung cancer screening
- Black patients less likely to be referred for screening or to complete follow-up



Increase Lung Cancer Screening in Vulnerable Populations

• Support

 Bristol Myers Squibb Foundation support for a 5-year initiative to enhance lung cancer screening through the Jefferson Health System

• Aims

- Engage a health system, health plans, patients, and other stakeholders in a "learning community" dedicated to increasing lung cancer screening in vulnerable populations
- Develop and test an outreach intervention strategy that would identify and address barriers to population use of a centralized screening program

Lung

Carcer

sparities

- Catalyze support for intervention implementation
- Evaluate learning community engagement and implementation processes and outcomes


Sidney Kimmel Cancer Center Jefferson Health Lung Cancer Learning Community LC2 Jane and Respira

Jane and Leonard Korman Respiratory Institute at Jefferson

TJUH Lung Cancer Screening program

- 2018-2020
- 1365 patients screened
- 33 lung cancers identified
- 21/33 were early stage

TJUH Lung Cancer Screening Program



• White • Black • Asian • Other

Sidney Kimmel Cancer Center Jefferson Health, NCI – designated

What can be done

- <u>Acknowledgment</u>
 - Disparities persist
- Education
 - Patients and Providers
- Specialization/Centralization
 - "Low quality" care disproportionally effects minority patients
- <u>Representation</u>
 - Diverse, culturally competent care teams







Olugbanga Okusanya, MD



Nathaniel Evans, MD



Tyler Grenda, MD



Scott Cowan, MD

Sidney Kimmel Cancer Center Jefferson Health. NCI - designated

Thank You



Sung Whang, DNP

Sidney Kimmel Cancer Center Jefferson Health | NCI - designated